Praveen Ramakrishnan, MD

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

Praveen Ramakrishnan, MD, assistant professor, Department of Internal Medicine, UT Southwestern Medical Center, discusses updates in diffuse large B-cell lymphoma (DLBCL) that were presented at the 2019 ASH Annual Meeting.

Praveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).

Praveen Ramakrishnan, MD, discusses the benefit of CAR T-cell therapy in patients with mantle cell lymphoma.